LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
unknown
📅 Published: 2025-09-09 16:34
📰 Source: Yahoo
📝 Words: 18
📝 Article Content
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
📄 Summary
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2025-09-12 16:40:19
Updated At:
2025-09-12 16:40:19
Scraping Job ID:
N/A
Stock Mentions:
LLY - Eli Lilly and Company
Relevance: N/A